Clinical characteristics of patients participating in this study
| . | No. . |
|---|---|
| MDS | 88 |
| Low risk | 58 |
| RCUD/RCMD/5q−/MDS-U* | 38 |
| RARS | 20 |
| High risk | |
| RAEB 1/2* | 30 |
| MDS/MPN | 66 |
| CMML/aCML/JMML | 48 |
| MDS/MPN-U* (RARS-T) | 18 (11) |
| MPN | 52 |
| PV/PMF/ET | 16 |
| CML | 36 |
| AML | 109 |
| Primary AML | 55 |
| Secondary AML* | 54 |
| . | No. . |
|---|---|
| MDS | 88 |
| Low risk | 58 |
| RCUD/RCMD/5q−/MDS-U* | 38 |
| RARS | 20 |
| High risk | |
| RAEB 1/2* | 30 |
| MDS/MPN | 66 |
| CMML/aCML/JMML | 48 |
| MDS/MPN-U* (RARS-T) | 18 (11) |
| MPN | 52 |
| PV/PMF/ET | 16 |
| CML | 36 |
| AML | 109 |
| Primary AML | 55 |
| Secondary AML* | 54 |
MDS indicates myelodysplastic syndromes; RCUD, refractory cytopenia with unilineage dysplasia; RCMD, refractory cytopenia with multilineage dysplasia; MDS-U, MDS unclassifiable; RARS, refractory anemia with ring sideroblasts; RAEB, refractory anemia with excess blasts; MDS/MPN, MDS/myeloproliferative neoplasms; CMML, chronic myelomonocytic leukemia; aCML, atypical chronic myeloid leukemia; JMML, juvenile myelomonocytic leukemia; RARS-T, RARS associated with marked thrombocytosis; PV, polycythemia vera; PMF, primary myelofibrosis; ET, essential thrombocythemia; and AML, acute myeloid leukemia.
Eight cases included with therapy-related myeloid malignancies.